Compare Becton Dickinson and Co (BDX) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs JPMorgan Chase & Co — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while JPMorgan Chase & Co trades at $345.06 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 22× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | JPM | |
|---|---|---|
Market Cap | $41.51B | $911.47B |
Sector | Health | Financials |
52-Week High | $185.39 | $342.89 |
52-Week Low | $135.49 | $282.84 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 1.75% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
JPMorgan Chase (JPM) trades at $334.53, down 0.58% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with $181.85B revenue in 2025 and net income of $57.05B, though recent earnings were mixed with a Q4 2025 miss but Q1 and Q2 2026 beats. Analyst consensus is moderately bullish with a $369.67 price target. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
JPMorgan presents a solid investment case with robust profitability (31.61% net margin, 17.03% ROE) and reasonable valuation (P/E 14.69). Risks include geopolitical tensions impacting banking operations and cybersecurity threats from advanced AI. The stock offers upside to analyst targets but faces headwinds from economic uncertainty and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
